Trial Profile
Clinical Trial to Investigate the Duration of P-glycoprotein Inhibition After Oral Administration of HM30181AK Tablet in Healthy Male Subjects : An Open, Parallel Dose Group Design.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs HM 30181A (Primary) ; Loperamide
- Indications Cancer
- Focus Pharmacodynamics
- Sponsors Hanmi Pharmaceutical
- 10 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Aug 2009 New trial record